Chantix Faces FDA Safety Gauntlet After Pfizer Settles Product Liability Suits
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA advisory committees will discuss risk of serious neuropsychiatric adverse events with the smoking cessation drug at October meeting.